Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Parentheticals) (unaudited)

v3.22.1
Condensed Consolidated Balance Sheets (Parentheticals) (unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Payroll liabilities ($0.7 million and $0.4 million attributable to VIE) $ 2,383,977 $ 3,906,317
Deferred revenue from company clinics attributable to VIE $ 3,130,856 $ 3,191,892
Series A preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Series A preferred stock, shares authorized (in shares) 50,000 50,000
Series A preferred stock, shares issued (in shares) 0 0
Series A preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, shares issued (in shares) 14,493,049 14,451,355
Common stock, shares outstanding (in shares) 14,461,332 14,419,712
Treasury stock, shares (in shares) 31,717 31,643
Variable Interest Entity, Primary Beneficiary    
Payroll liabilities ($0.7 million and $0.4 million attributable to VIE) $ 700,000 $ 400,000
Deferred revenue from company clinics attributable to VIE $ 3,600,000 $ 3,500,000